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Diff  use large B cell lymphoma (DLBCL), the 
most common type of non-Hodgkin’s lym-
phoma, accounts for  30% of all lymphoma 
cases (1). DLBCL can be cured using anthra-
cycline-based chemotherapy regimens in just 
40–50% of patients, suggesting that DLBCL 
represents a heterogeneous disease (2). This 
concept was supported by several recent gene 
expression profi   ling studies distinguishing at 
least three diff   erent molecular DLBCL sub-
groups (3–7). These three subgroups have been 
termed germinal center B cell–like (GCB) DL-
BCL, activated B cell–like (ABC) DLBCL, and 
primary mediastinal B cell lymphoma (PMBL). 
The DLBCL subgroups diff  er not only with 
respect to their gene expression profi  les, but they 
also have signifi  cantly diff  erent overall survival 
rates and use distinct oncogenic pathways (8). 
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To elucidate the mechanisms underlying chromosomal translocations in diffuse large B cell 
lymphoma (DLBCL), we investigated the nature and extent of immunoglobulin class switch 
recombination (CSR) in these tumors. We used Southern blotting to detect legitimate and 
illegitimate CSR events in tumor samples of the activated B cell–like (ABC), germinal 
center B cell–like (GCB), and primary mediastinal B cell lymphoma (PMBL) subgroups of 
DLBCL. The frequency of legitimate CSR was lower in ABC DLBCL than in GCB DLBCL and 
PMBL. In contrast, ABC DLBCL had a higher frequency of internal deletions within the 
switch 𝗍 (S𝗍) region compared with GCB DLBCL and PMBL. ABC DLBCLs also had frequent 
deletions within S𝗄 and other illegitimate switch recombinations. Sequence analysis re-
vealed ongoing S𝗍 deletions within ABC DLBCL tumor clones, which were accompanied by 
ongoing duplications and activation-induced cytidine deaminase–dependent somatic muta-
tions. Unexpectedly, short fragments derived from multiple chromosomes were interspersed 
within S𝗍 in one case. These fi  ndings suggest that ABC DLBCLs have abnormalities in the 
regulation of CSR that could predispose to chromosomal translocations. Accordingly, aber-
rant switch recombination was responsible for translocations in ABC DLBCLs involving 
BCL6, MYC, and a novel translocation partner, SPIB. CORRESPONDENCE
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By these criteria, the DLBCLs can be viewed as distinct 
  diseases that arise from B lymphocytes at diff  erent stages 
of diff  erentiation.
GCB DLBCL tumors express many genes that are char-
acteristic for normal germinal center B cells, suggesting that 
this lymphoma subgroup arises from B cells at the germinal 
center stage of diff  erentiation, probably from the highly 
proliferative centroblasts (3, 4, 6). Characteristically, GCB 
DLBCLs express the key transcriptional repressor BCL6 and 
consequently lack expression of its target genes (9, 10).
In contrast, the gene expression profi  le of ABC DLBCL 
suggests that this lymphoma subgroup is derived from B cells 
that are in the process of diff  erentiating from germinal center 
B cells to plasma cells (4, 6). This hypothesis was based on the 
observation that ABC DLBCLs have down-regulated most 
of the germinal center B cell signature genes, including 
BCL6. Instead, ABC DLBCLs express a key regulator of the 
secretory phenotype of plasma cells, XBP-1, as well as many 
of its downstream target genes (6, 11). Strong support for 
this hypothesis was provided by the recent demonstration 
that genomic mutations, deletions, and rearrangements of the 
gene encoding Blimp-1 are recurrent in ABC DLBCLs but 
are not present in GCB DLBCLs (12, 13). Blimp-1 is the 
master regulator of plasmacytic diff  erentiation that represses 
directly or indirectly the entire gene expression program of 
mature B cells (14). Thus, the inactivation of Blimp-1 in 
roughly one quarter of ABC DLBCL cases provides direct 
evidence that a block in diff  erentiation is a key event in the 
pathogenesis of this lymphoma type.
The third subgroup, PMBL, has a characteristic gene 
  expression signature that distinguishes it from GCB DLBCL 
and ABC DLBCL, but which it shares with the malignant 
cells of Hodgkin lymphoma (5, 7). PMBL characteristically 
arises in the mediastinum and, upon pathological examina-
tion, a thymic remnant can often be found associated with 
the tumor mass. This fi  nding suggests that PMBL arises from 
a rare B cell subpopulation that resides in the thymus (15). 
PMBLs express some genes in common with GCB DLBCLs, 
including BCL6, but do not express the ABC DLBCL signa-
ture genes and, particularly, do not express genes associated 
with plasmacytic diff  erentiation (8).
An important event after activation of mature B cells by 
antigen is Ig class switch recombination (CSR), which can 
occur within the germinal center or during the extrafollicular 
activation of B cells. CSR is a recombination and deletion 
mechanism that juxtaposes a downstream Ig heavy chain 
(CH) segment to the rearranged VHDHJH segment, thereby 
switching the Ig isotype of a B cell from IgM to IgG, IgA, or 
IgE. CSR occurs within the highly repetitive switch regions 
located 5′ of each constant region (16, 17). The enzyme 
  activation-induced cytidine deaminase (AID) is the B cell–
specifi  c factor that is absolutely required for CSR (18–22). In 
the current understanding of CSR, AID initiates the reaction 
by creating double-strand DNA breaks in the switch regions. 
These double-strand DNA breaks recruit and activate DNA 
damage response proteins, including ataxia-teleangiectasia, 
histone H2AX, and 53BP1, which coordinate a ligation re-
action that uses the enzymatic machinery of the nonhomolo-
gous end joining reaction (23–27). CSR is precisely regulated 
by extracellular signals that infl  uence the choice of which 
downstream switch regions are involved in the reaction. This 
regulation is achieved by the production of sterile mRNA 
transcripts that traverse a switch region and facilitate the re-
cruitment and action of AID (17).
The elaborate controls governing CSR can, however, go 
awry as indicated by the frequent subversion of CSR to cre-
ate aberrant switch translocations in multiple myeloma and 
other lymphoid malignancies (28). Indeed, experimental 
overexpression of AID can directly promote chromosomal 
translocations between the Ig heavy chain locus and c-MYC 
in mouse B lymphocytes (29, 30). Interestingly, AID is one 
of the few germinal center genes that is more highly expressed 
in ABC DLBCL than in GCB DLBCL (6), which may be due 
to the high expression of IRF4 (3, 4, 6), a transcription factor 
that directly or indirectly increases AID expression (31, 32).
Given the high expression of AID in ABC DLBCL and 
the ability of AID to promote aberrant class switch transloca-
tions, we investigated the nature and extent of CSR events in 
this lymphoma type in comparison to other subgroups of 
DLBCL. To this end, we probed the genomic structure of 
the Ig switch regions by Southern blotting in 22 DLBCL cell 
lines and 92 DLBCL patient samples, which revealed signifi  -
cant diff  erences in the frequency of CSR between the three 
subgroups. Unexpectedly, we discovered an abnormality in 
switch recombination in ABC DLBCLs that led to frequent 
nonproductive intra-switch CSR, insertion of foreign chro-
mosomal DNA into the Ig locus, and chromosomal trans-
locations involving the switch regions.
RESULTS
Class switch recombination events in subgroups of DLBCL
To investigate the frequency and nature of CSR events in 
tumors of diff  erent DLBCL subgroups, we used a Southern 
blot assay that can detect both legitimate CSR events and il-
legitimate recombination and deletion events involving the 
Ig switch regions (28, 33). This assay uses three diff  erent pairs 
of Southern blot probes that hybridize either 5′ or 3′ of the 
Sμ, Sγ, and Sα switch regions (Fig. 1). With the Sμ probe 
pairs, a single hybridizing fragment is present in germ line 
DNA, whereas the Sγ probes hybridize to four germ line 
fragments representing Sγ1, Sγ2, Sγ3, and Sγ4, and the Sα 
probes hybridize to two germ line fragments representing 
Sα1 and Sα2. Genomic DNAs from 22 DLBCL cell lines and 
92 DLBCL patient samples were digested with either of two 
restriction enzymes (HindIII or SphI) and subsequently hy-
bridized with the diff  erent probes. A switch region in germ 
line confi  guration will be refl  ected by a restriction fragment 
that hybridizes with the corresponding 5′ and 3′ switch 
probes and that is also present in the placental control DNA 
(Fig. 1, A and F). A legitimate switch event,  such as be-
tween Sμ and Sγ, creates a restriction fragment that will be 
detected by the 5′ Sμ and the 3′ Sγ probes (Fig. 1, B and F). JEM VOL. 204, March 19, 2007  635
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Legitimate switch recombinations may also occur between 
downstream switch regions, such as between Sγ and Sα. 
  Inversion CSR events, such as between Sμ and Sγ, generate 
a restriction fragment that either hybridizes with the 5′ switch 
μ and γ probes or with the two 3′ switch probes (Fig. 1 C). 
An illegitimate switch recombination event is operationally 
defi  ned by a restriction fragment that hybridizes with only 
one switch region probe (Fig. 1 F). This may be caused by a 
chromosomal translocation (Fig. 1 D), an insertion of foreign 
sequences into a switch region, a polymorphism or mutation 
of the restriction enzyme binding site, or an atypical deletion 
within the Ig heavy chain locus. Intra-switch recombination 
events may occur in which part of a switch region is deleted 
without resulting in legitimate switch recombination, and 
these can be detected reliably when they occur in Sμ (Fig. 1, 
E and F). The human Ig locus contains four Sγ and two Sα 
regions. CSR can potentially join diff  erent Sγ regions or dif-
ferent Sα regions together. Using the Southern blot assay, 
these events would be impossible to distinguish from intra-Sγ 
deletions and intra-Sα deletions, respectively.
The analysis of 6 ABC DLBCL and 16 GCB DLBCL 
cell lines demonstrated diff  erences in the frequency of legiti-
mate switch recombination events (Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20062041/ DC1). 
Whereas none of the ABC DLBCL cell lines had a germ line 
confi  guration of a switch region, four (25%) of the GCB DL-
BCL lines had only germ line switch regions. 1 ABC DLBCL 
cell line (17%) had a legitimate switch involving Sμ and 
Sγ, whereas 11 GCB DLBCL cell lines (69%) had a legiti-
mate switch from Sμ to either Sγ or Sα or from Sα to Sγ. 
Figure 1.  Analysis of class switch recombination by Southern blot. 
(A–E) The position of HindIII restriction sites are shown. Thick lines indicate 
binding sites of respective probes. (A) Germ line confi  guration of switch μ 
and switch γ regions. (B) Legitimate switch μ to γ, detected by 5′ Sμ and 
3′ Sγ probe. (C) Inversion switch μ to γ, detected by 5′ Sμ and 5′ Sγ probe. 
(D) Chromosomal translocation, detected by 5′ Sμ probe. (E) Intra-switch μ 
deletion, detected by 5′ Sμ and 3′ Sμ probe. (F) Applied restriction enzyme 
is indicated below lanes. The probes used for hybridization are shown above 
each lane. Panel I: Restriction digest of placental DNA shows germ line con-
fi  guration. Panel II: Restriction digest of patient sample 529 genomic DNA. 
Arrows indicate legitimate switch recombination μ to γ. Panel III: Restric-
tion digest of SUDHL-2 genomic DNA. Arrow indicates illegitimate switch 
recombination detected by 5′ Sμ probe. Panel IV: Restriction digest of pa-
tient sample 1002 genomic DNA. Arrows indicate intra-switch μ deletion.636  CSR IN DLBCL LYMPHOMA | Lenz et al.
  Illegitimate CSR events were detected in half of the ABC 
DLBCL and GCB DLBCL cell lines.
Analysis of 92 primary biopsy samples revealed diff  er-
ences between ABC DLBCL and GCB DLBCL with re-
spect to the nature and extent of CSR (Fig. 2 and Table S2, 
which is available at http://www.jem.org/cgi/content/full/
jem.20062041/DC1). Among 50 ABC DLBCL cases, the 
switch regions were in germ line confi  guration in only 4 
(8%). Only 15 cases (30%) had a legitimate switch recombi-
nation. 28 cases (56%) showed an illegitimate switch recom-
bination event, and 6 cases (12%) had an inversion switch 
recombination between Sμ and Sγ or Sα (5 cases with in-
version switch recombination between Sμ and Sγ, and 
1 case with inversion switch recombination between Sμ and 
Sα). Strikingly, 24 ABC DLBCLs (48%) had intra-Sμ dele-
tion events (Fig. 1, E and F), and 64% of cases showed a 
  deletion/recombination in Sγ.
As with ABC DLBCLs, only a small fraction of GCB 
DLBCLs had switch regions in the germ line confi  guration 
(4 out of 31 cases; 13%). However, legitimate CSR events 
were more common in GCB DLBCLs, occurring in 18 of 31 
cases tested (58%) compared with ABC DLBCLs (P = 0.012). 
Conversely, GCB DLBCLs had lower frequencies of several 
aberrant class switch events compared with ABC DLBCLs, 
including illegitimate switch recombination (32%; P = 
0.037), inversion switch recombination (0%; P = 0.045), 
  intra-Sμ deletion (13%; P = 0.0012), and intra-Sγ deletion/
recombination (29%; P = 0.002).
Of 11 PMBL cases available for analysis, 7 (64%) had legit-
imate CSR events, which was signifi  cantly more than among 
ABC DLBCLs (P = 0.035). Illegitimate CSR events were 
detected in fi  ve cases (45%), and inversion switch events were 
detected in three cases (27%). In contrast to ABC DLBCLs, 
intra-Sμ deletions were not present in any PMBL   patient 
sample analyzed (P = 0.003).
As a control, we investigated CSR events in mucosa-
  associated lymphoid tissue (MALT) lymphoma because this 
postgerminal center lymphoma type has been reported to 
have aberrant CSR events in some cases (34). Like ABC 
DLBCL, MALT lymphomas had a relatively low frequency 
of legitimate CSR events (6/17 cases investigated; 35%). 
However, in contrast to ABC DLBCLs, none of the MALT 
lymphomas had intra-Sμ deletions (P = 0.0004). MALT 
lymphomas also had fewer illegitimate CSR events than 
ABC DLBCLs (29%; P = 0.058) and intra-Sγ deletions/ 
recombinations (29%; P = 0.013).
In summary, ABC DLBCLs had a lower frequency of 
  legitimate class switch recombination events relative to the 
other lymphoma subtypes and a higher frequency of intra-Sμ 
deletion, intra-Sγ deletion/recombination events as well as 
illegitimate switch recombination events. Intra-Sα deletion/
recombination events were detected, but there were no sig-
nifi  cant diff  erences in frequency of these events among the 
lymphoma subtypes (Table S2).
Expression of AID in lymphoma subsets
AID mRNA levels were assessed in 245 primary lymphoma 
specimens with the use of Aff  ymetrix oligonucleotide micro-
arrays (Fig. 3 A). Highest levels of AID expression were ob-
served in ABC DLBCL and PMBL, and these lymphoma 
types had, respectively, threefold and 2.5-fold higher expres-
sion than GCB DLBCL (ABC DLBCL vs. GCB DLBCL, 
P = 0.00006; PMBL vs. GCB DLBCL, P = 0.01). The pre-
germinal center lymphoma types, mantle cell lymphoma and 
small lymphocytic lymphoma, both had low levels of AID 
expression compared with any of the DLBCL subgroups as 
Figure 2.  Summary of the analysis of class switch recombina-
tion in 92 DLBCL and 17 MALT lymphoma patients. (A) Germ 
line. No signifi  cant differences can be observed between the different 
lymphoma subtypes. (B) Legitimate switch recombination. GCB DLBCL 
and PMBL show a signifi  cantly higher frequency of legitimate switch 
recombinations compared with ABC DLBCL (ABC   DLBCL vs. GCB 
DLBCL, P = 0.012; ABC DLBCL vs. PMBL, P = 0.035). (C) Inversion switch 
recombination. ABC DLBCL shows a signifi  cantly higher rate of inver-
sion switch recombinations compared with GCB DLBCL (ABC DLBCL vs. 
GCB DLBCL, P = 0.045). (D) Intra-switch μ deletions. ABC DLBCL shows 
a signifi  cantly higher rate of intra-switch μ deletions compared with 
GCB DLBCL, PMBL, or MALT (ABC DLBCL vs. GCB DLBCL, P = 0.0012; 
ABC DLBCL vs. PMBL, P = 0.003; ABC DLBCL vs. MALT, P = 0.0004). 
(E) Intra-switch γ deletion/recombination. ABC DLBCL shows a signifi  -
cantly higher rate of intra-switch γ deletion/recombination compared 
with GCB DLBCL and MALT (ABC DLBCL vs. GCB DLBCL, P = 0.002; 
ABC DLBCL vs. MALT, P = 0.013). (F) Illegitimate switch recombination. 
ABC DLBCL shows a signifi  cantly higher rate of illegitimate switch re-
combinations compared with GCB DLBCL (ABC DLBCL vs. GCB DLBCL, 
P = 0.037).JEM VOL. 204, March 19, 2007  637
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did the post-germinal center entity, MALT lymphoma (ABC 
DLBCL vs. mantle cell lymphoma, P = 2.2 × 10−16; 
ABC DLBCL vs. small lymphocytic lymphoma, P = 0.0003; 
ABC DLBCL vs. MALT, P = 2.16 × 10−5).
Having identifi  ed a small subset of DLBCLs in which the 
Ig switch regions were in germ line confi  guration, we inves-
tigated whether these lymphomas might have lower levels of 
AID expression. Indeed, among ABC DLBCLs, cases with 
germ line switch regions had eightfold lower expression 
compared with non-germ line cases (Fig. 3 B; P = 0.0012). 
Likewise, those GCB DLBCLs with germ line switch regions 
had lower AID expression than their non-germ line counter-
parts (P = 0.09).
Structure of intra-S𝗍 deletions
To characterize intra-Sμ deletions further, we amplifi  ed the 
Sμ regions from four ABC DLBCL cases (cases 756, 692, 
645, and 428) that had putative intra-Sμ deletions based on 
the Southern blot assay. All intra-Sμ deletions were con-
fi  rmed by PCR (Fig. 4 A). Unexpectedly, however, case 
428, which had a single intra-Sμ deletion band using the 
Southern blot assay, yielded a cluster of bands ranging from 
 2.7 to  3.9 kb in size after PCR for the Sμ region. This 
fi  nding suggested that there might be intra-clonal variation in 
the structure of the intra-Sμ deletions.
To examine this possibility, we cloned the amplifi  ed 
intra-Sμ deletion bands of the four ABC DLBCL samples 
and determined the sequence of three to fi  ve clones per case. 
The molecular clones derived from a single case were re-
markably diverse, showing 1–19 separate deletion events 
within Sμ (Table I, Fig. 4 B, and Fig. S1, which is available 
at http://www.jem.org/cgi/content/full/jem.20062041/DC1). 
Even in cases in which the Sμ PCR product appeared to be 
a single band, the clones obtained were diverse in sequence.
We next examined the 5′ end of the amplifi  ed Sμ region 
in detail for the presence of somatic mutations. From each 
case, we obtained molecular clones that had a large number 
of somatic mutations (Table I, Fig. 4 B, and Fig. S1). These 
mutations occurred most frequently at RGYW motifs, 
strongly suggesting that they were caused by AID (Fig. S2, 
available at http://www.jem.org/cgi/content/full/jem
.20062041/DC1). In some instances, diff  erent molecular 
clones from the same case had distinct somatic mutations 
whereas other molecular clones had no mutations.
As a control, we performed a similar sequence analysis of 
the Sμ region in two ABC DLBCL cases in which Sμ was in 
germ line confi  guration by Southern blot analysis. As ex-
pected, no deletion was detected in the amplifi  ed Sμ regions 
from these cases by PCR. Further, these two cases had signif-
icantly fewer somatic mutations in Sμ than ABC DLBCL 
cases with intra-Sμ deletions.
In addition to deletions and mutations, sequence analysis 
revealed several duplications of Sμ segments of up to 40 bp 
in length (Table I and Fig. S1). Unexpectedly, we also de-
tected insertions of short DNA segments derived from other 
chromosomes into the Sμ region of one of the four ABC 
DLBCL cases analyzed (Fig. 4, B and C). These insertions, 
which varied in length from 146 to 160 bp, were derived 
from chromosomes 17, 12, and 4 and were arranged in tan-
dem with no gaps between the insertions (Fig. 4 C). These 
segments were situated within a Sμ deletion of 10 bp. Inter-
estingly, one of the three clones analyzed from this case had a 
19-bp deletion within the inserted chromosome 4 sequence 
(Fig. 4 B). This fi  nding suggests that AID is able to create 
breaks and deletions in ectopic sequences that are inserted 
into the Sμ region.
Figure 3.  Relative AID mRNA expression in different lymphoma 
subtypes. (A) ABC DLBCLs and PMBLs express the highest level of AID 
mRNA. (B) Comparison of AID mRNA expression in ABC DLBCL and GCB 
DLBCL germ line cases versus non-germ line cases. Non-germ line cases 
express higher AID mRNA compared with germ line cases.
Table I.  Sequence analysis of Sμ deletions in ABC DLBCL and 
GCB DLBCL patient samples
Sample DLBCL 
subtype
No. of Sμ 
deletions
No. of somatic 
mutationsa
No. of 
duplications
428 ABC DLBCL 19 n.a. 0
645 ABC DLBCL 13 n.a. 3
692 ABC DLBCL   9 n.a. 2
756 ABC DLBCL   5 3 0
459 GCB DLBCL 11 3 0
742 GCB DLBCL 6 6 1
n.a., not available, as investigated 250-bp segment partly or completely deleted. 
aSomatic mutations determined in 250-bp segment at 5′ end of Sμ.638  CSR IN DLBCL LYMPHOMA | Lenz et al.
For each of the four cases, we were able to organize all of 
the Sμ deletions, mutations, duplications, and insertions into 
lineage models of the stepwise accumulation of these events in 
individual molecular clones (Fig. 4 B and Fig. S1). The fact 
that such lineage diagrams can be drawn is consistent with on-
going molecular alterations of the Sμ regions within the ma-
lignant clones. In three of four cases, the fi  rst abnormality that 
occurred was one or several internal deletions. Subsequently, 
each clone underwent several steps of mutations, internal tan-
dem duplications, and insertions of DNA from other chromo-
somes. Finally, most of the clones sustained one or more Sμ 
deletions. Thus, multiple molecular mechanisms that perturb 
Sμ structure were ongoing and interspersed in time after ma-
lignant transformation of a B cell into ABC DLBCL.
Although intra-Sμ deletions were much less frequent in 
GCB DLBCLs than in ABC DLBCLs (Fig. 2 D), we investi-
gated whether ongoing intra-clonal Sμ alterations could also 
occur in GCB DLBCL. To this end, we amplifi  ed the Sμ 
  regions of two GCB DLBCL patient samples (cases 742 and 
459) that had intra-Sμ deletions by the Southern blot assay. 
In both cases, intra-Sμ deletions were confi  rmed by PCR 
(Fig. 4 A). Sequence analysis revealed clonal heterogeneity in 
both cases, with 6–11 deletions per case, various somatic mu-
tations, and a duplication of 194 bp in GCB DLBCL case 742 
(Table I). Thus, GCB DLBCL and ABC DLBCL can appar-
ently use similar aberrant CSR mechanisms, albeit with dif-
ferent frequencies.
Switch translocations in DLBCL
As assessed by the Southern blotting, ABC DLBCL had the 
highest frequency of illegitimate switch recombination events 
(Fig. 2). To determine whether these illegitimate events 
might represent chromosomal translocations involving 
the switch regions, we fi  rst performed fl  uorescence in situ hy-
bridization (FISH) using CH and VH probes to determine the 
presence of IgH translocations. We investigated 10 DLBCL 
Figure 4.  Analysis of intra-switch μ deletions. (A) PCR amplifi  cation 
of intra-switch μ deletions (ethidium bromide–stained 0.8% agarose gel). 
Asterisks indicate cloned PCR bands for sequence analysis. (B) Lineage 
model of aberrations in ABC DLBCL patient sample 428. d, deletion; 
M, mutation; I, insertion. Open circles represent putative clonal precursors. 
Numbers refer to GenBank accession number NG_001019.4. (C) Sequence 
analysis of DNA insertions into Sμ in ABC DLBCL case 428. bp numbers 
refer to accession number Hs17_10875 for chromosome 17, accession 
number Hs12_29578 for chromosome 12, and accession number Hs4_16510 
for chromosome 4.JEM VOL. 204, March 19, 2007  639
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cell lines (2 ABC DLBCL cell lines: OCI-Ly10, and 
SUDHL2, and 8 GCB DLBCL cell lines: NUDHL-1, 
NUDUL-1, OCI-Ly1, OCI-Ly2, OCI-Ly-8, SUDHL-4, 
Toledo, and RCK8) that had an illegitimate switch recombi-
nation phenotype by Southern blotting. As a control, we an-
alyzed the ABC DLBCL cell line U2932 that did not show 
an illegitimate switch recombination. IgH translocations 
were detected by FISH in all 10 DLBCL cell lines with the 
illegitimate CSR phenotype, but not in U2932, demonstrat-
ing that the majority of illegitimate CSR events represent 
chromosomal translocations.
We next investigated whether two oncogenes of impor-
tance in DLBCL, MYC and BCL6, were involved in illegiti-
mate switch translocations. FISH analyses of DLBCL samples 
were performed using “break-apart” probes spanning the 
MYC and BCL6 loci, revealing MYC disruptions in 7% of 
cases analyzed (n = 87; reference 35) and BCL6 disruptions 
in 19% of cases analyzed (n = 133; unpublished data). Some 
of these positive cases were investigated further using long-
distance PCR assays to detect MYC or BCL6 translocations 
into the Sμ or Sγ regions. These assays revealed an MYC 
translocation into the Sγ region in one ABC DLBCL case 
and a BCL6 translocation into the Sμ region in another (Fig. 
5 A). In cell lines with illegitimate switch CSR events, long-
distance PCR demonstrated a MYC-Sγ translocation in the 
GCB DLBCL cell line NUDUL-1 (Fig. 5 A).
Additionally, we investigated whether a t(14;19) trans-
location in the ABC DLBCL cell line OCI-Ly3 might be the 
result of aberrant switch recombination. FISH using a whole 
chromosome 19 painting probe revealed that OCI-Ly3 cells 
show a t(14;19) as well as a complicated translocation involv-
ing chromosomes 19, 22, 4, and 18 (unpublished data; Fig. 5 B). 
A variety of BAC probes from chromosome 19 were used in 
FISH analyses to narrow the region of chromosome 19 in-
volved in the translocations (unpublished data). Ultimately, 
three BAC probes in the vicinity of the SPIB gene were 
identifi  ed that clustered around the translocation breakpoint 
(Fig. 5 B). The t(14;19) derivative chromosome hybridized 
Figure 5.  Switch translocations in DLBCL. (A) PCR for detection of 
BCL6/MYC switch translocations (ethidium bromide–stained 0.8% agarose 
gel). Lane 1, Sγ-MYC translocation in ABC DLBCL case 1000; lane 2, 
Sγ-MYC translocation in GCB DLBCL cell line NUDUL-1; lane 3, Sμ-BCL6 
translocation in ABC DLBCL case 709. (B) Whole chromosome painting 
of chromosome 19 detects t(14; 19) and t(19; 22; 4; 18). Hybridization 
of t(14; 19) with spanning and telomeric BAC SPIB probes. No hybridiza-
tion with centromeric BAC probe. Hybridization of t(19; 22; 4; 18) 
with centromeric and spanning BAC SPIB probe, no hybridization with 
telomeric probe. (C) Detection of switch γ-SPIB translocation by Southern 
blot in OCI-Ly3. (D) Sequence analysis of switch γ-SPIB translocation. 
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with BAC probes spanning or telomeric to the SPIB gene, 
but not with a BAC probe centromeric to SPIB. This sug-
gested that the translocation breakpoint was 5′ of the tran-
scriptional start site of SPIB. In contrast, the t(19; 22; 4; 18) 
hybridized with the centromeric BAC probe and weakly 
with the spanning BAC probe (Fig. 5 B).
We next used Southern blot hybridization to confi  rm 
the SPIB translocation that was detected by FISH. With 
OCI-Ly3 cells, a 332-bp probe binding  200 bp 3′ of the 
start codon of SPIB hybridized to one germ line fragment 
and to a second smaller fragment (Fig. 5 C), whereas only 
the germ line fragment was observed in other lymphoma cell 
lines (unpublished data). Finally, we were able to amplify the 
translocation breakpoint using PCR primers derived from 
the Sγ region and from the 5′ end of SPIB. Sequence analy-
sis confi  rmed that the breakpoint occurred 265 bp 5′ of the 
SPIB transcriptional start site and joined SPIB with the Sγ3 
region (Fig. 5 D). Additionally, the translocated Sγ3 region 
sustained a second deletion of 2,858 bp, demonstrating that 
the processes responsible for intra-switch deletion and switch 
translocation can target the same Ig allele (Fig. 5 D). As a 
consequence of this translocation, the intact SPIB coding 
  region was placed in proximity to the Ig 3′α enhancer (Fig. 
5 D), resulting in a high level of SPIB mRNA expression 
compared with most other DLBCL biopsy samples and cell 
lines (not depicted).
DISCUSSION
Using a Southern blot assay, we have discovered signifi  cant 
diff  erences in the frequency and character of CSR among 
three molecular subtypes of DLBCL. Unexpectedly, almost 
half of the ABC DLBCLs had internal deletions in Sμ, events 
that were present rarely among GCB DLBCLs (13%) and ab-
sent among PMBLs and MALT lymphomas. Furthermore, 
64% of ABC DLBCL cases had abnormal CSR events in-
volving Sγ regions, which occurred much less commonly in 
GCB DLBCL (29%), PMBL (36%), and MALT lymphoma 
(29%). In normal B cells, intra-Sμ deletion occurs in only 
12.5–18% of cells (36, 37), and intra-Sγ deletion/recombina-
tion events are extremely rare (37). Therefore, the high fre-
quency of both intra-Sμ and intra-Sγ deletion/recombination 
events in ABC DLBCL strongly suggests that CSR is func-
tionally impaired in this lymphoma type, potentially predis-
posing this lymphoma type to chromosomal translocations. 
Conversely, legitimate CSR was signifi  cantly less common in 
ABC DLBCL than GCB DLBCL or PMBL. Consistent with 
this fi  nding, ABC DLBCLs express IgM mRNA at signifi  -
cantly higher levels than do GCB DLBCLs (6).
Constitutive overexpression of AID seems a likely con-
tributor to the aberrant CSR in ABC DLBCL. Normal B 
lymphocytes transcriptionally activate AID upon stimula-
tion by antigen or mitogens, and this up-regulation requires 
the activity of the transcription factor IRF4 (31, 32). ABC 
DLBCLs have high expression of IRF4 due to constitutive 
NF-κB pathway activation (3, 4, 38, 39), which may account 
for the high AID expression in ABC DLBCL despite the fact 
that most other germinal center B cell signature genes are 
down-regulated (6). Indeed, of all lymphoma types studied, 
AID mRNA is highest in ABC DLBCL (Fig.  3) and, con-
sequently, AID protein is more highly expressed in ABC 
DLBCL than in GCB DLBCL (40). Interestingly,  the few 
ABC DLBCLs that lacked AID expression were those that 
had a germ line confi  guration of the Ig switch regions. This 
result is consistent with the hypothesis that AID action is re-
quired for the aberrant CSR that characterizes the majority 
of ABC DLBCLs.
In normal B cell responses to antigen, AID expression is 
limited to a short window during which the B cell is diversi-
fying its IgV regions in the germinal center reaction. AID 
expression is normally extinguished during plasmacytic dif-
ferentiations, thereby limiting the exposure of B cells to this 
potentially mutagenic enzyme. In contrast, constitutive AID 
expression in ABC DLBCL may expose the genome of this 
tumor type to repeated mutation and DNA strand breaks. 
Sequence analysis of the intra-Sμ deletions in ABC DLBCL 
revealed that AID was constitutively active in the malignant 
clone over many generations. These Sμ regions contained as 
many as 19 independent deletions that were interspersed with 
somatic mutations targeted at AID hot spots. This remarkably 
high frequency of switch region deletions is unprecedented 
in analyses of switch regions from normal mouse B cells. 
These deletions and mutations could be organized into lin-
eage diagrams that imply that AID-dependent single-stranded 
and double-stranded breaks were being generated over many 
generations of the ABC DLBCL clones. GCB DLBCLs had 
aberrant CSR events less commonly, but in two patient sam-
ples we identifi  ed ongoing deletions, mutations, and duplica-
tions in Sμ. GCB DLBCLs expressed AID mRNA at levels 
that were lower than in ABC DLBCL but still higher than in 
mantle cell lymphoma, small lymphocytic lymphoma, and 
MALT lymphoma (Fig. 3 A). Because AID is likely to par-
ticipate in the Sμ abnormalities, the level of AID in GCB 
DLBCL is apparently suffi   cient for aberrant CSR. Nonethe-
less, the signifi  cantly higher AID expression in ABC DLBCL 
may contribute to the higher frequency of Sμ deletions in 
this DLBCL subtype.
However, none of the PMBL samples showed intra-Sμ 
deletions despite having AID expression levels that were 
comparable to those in ABC DLBCLs. Therefore, it is un-
likely that high AID expression is the only molecular ab-
normality that contributes to aberrant CSR in ABC DLBCL. 
The fact that intra-switch deletions predominated over legiti-
mate switch recombination suggests that ABC DLBCLs may 
have defects in the process of “synapsis” that brings two dif-
ferent switch regions together before recombination (17). 
Genetic defi  ciency in three DNA repair proteins, H2AX, 
53BP1, and ataxia-teleangiectasia, reduces legitimate CSR in 
mouse B cells while allowing intra-Sμ deletions to occur 
(25, 27, 37, 41, 42), leading to the hypothesis that these pro-
teins may facilitate the formation of a protein lattice that 
physically links switch regions that have sustained AID-
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DLBCLs in contrast to PMBL may have a genetic or func-
tional defi  ciency in one of these DNA repair proteins.
One of the most unanticipated fi  ndings in the present 
study was the insertion of foreign DNA segments within the 
Sμ region of one ABC DLBCL case, which may refl  ect a 
dysregulation of CSR that predisposes this lymphoma type to 
chromosomal translocations. The inserted DNA segments 
originated from three chromosomes and were ligated in tan-
dem without homologous sequences at the junctions, sug-
gesting that they were joined by the NHEJ mechanism. 
These insertions have not been reported in switch regions 
from normal B cells (37), further supporting the hypothesis 
that CSR is dysregulated in ABC DLBCL. However, it has 
been published that in one case of MALT lymphoma, a 336-bp 
segment from the ARNT2 gene on chromosome 15 was in-
serted into Sμ, suggesting that this aberrant CSR mechanism 
also occurs in other lymphoma types (34). The molecular 
mechanism responsible for the blunt end insertion of foreign 
DNA into switch region remains unknown.
We speculate that the extraordinary frequency of intra-
switch deletions and the insertions of ectopic DNA into Sμ 
in ABC DLBCLs may predispose these lymphomas to chro-
mosomal translocations. In the Sγ3-SPIB translocation in the 
OCI-Ly3 cell line, the translocated switch region had also 
sustained an intra-switch deletion, raising the possibility that 
these events might be mechanistically linked. By the South-
ern blot assay, 56% of ABC DLBCLs had illegitimate CSR 
events, and these events were less frequent in the other DL-
BCL subtypes and in MALT lymphoma. At least some of 
these illegitimate CSR events represent chromosomal trans-
locations as we were able to identify illegitimate switch trans-
locations involving the BCL6,  MYC, and SPIB genes in 
ABC DLBCLs. Also, all cell lines that had illegitimate CSR 
events in the Southern blot assay had IgH translocations that 
were demonstrable by FISH. AID is a likely candidate to 
mediate these chromosomal translocations because it has been 
shown to be required for spontaneous MYC/IgH transloca-
tions that occur in IL-6-transgenic (29), 53BP1−/− (30), and 
H2AX−/− (43) mice. Compared with resting blood mature 
B cells, ABC DLBCLs have 26-fold higher AID mRNA ex-
pression (unpublished data). In this regard, it is notable that 
ectopic overexpression of AID in mouse B cells by  10-fold 
was suffi   cient to cause chromosomal translocations linking 
the MYC locus to the IgH locus (30). Thus, it is certainly 
plausible that the high expression of AID in ABC DLBCL 
contributes to the higher frequency of intra-Sμ deletion and 
illegitimate CSR in this lymphoma type. AID could contrib-
ute to an initiating chromosomal translocation event involv-
ing a potent oncogene such as MYC and BCL6 or could act 
later in malignant transformation to generate translocations 
that drive clonal progression. However, because PMBL and 
ABC DLBCL express AID mRNA at approximately equiva-
lent levels, it is likely that ABC DLBCLs have additional 
mechanisms that deregulate CSR given the fact that this lym-
phoma type has higher intra-Sμ and intra-Sγ deletions and 
higher illegitimate CSR events than PMBL.
The novel switch translocation involving the SPIB gene 
that we identifi  ed in the ABC cell line OCI-Ly3 highlights 
the potential biological importance of the switch transloca-
tions in ABC DLBCL. SPIB is an Ets family transcription 
factor that is expressed exclusively in mature B cells, T cell 
progenitors, and plasmacytoid dendritic cells (44, 45). SPIB is 
required for full B cell receptor signaling and T cell–depen-
dent antibody responses (46). SPIB is central to the germinal 
center reaction because germinal centers in SPIB-defi  cient 
mice are smaller in size, persist for a shorter duration after 
immunization, and contain more apoptotic cells than those in 
wild-type animals (46). The importance of SPIB as a regula-
tor of mature B cell function is also emphasized by the fact 
that it is directly repressed by Blimp-1 during plasmacytic 
diff  erentiation (14). Interestingly, SPIB is signifi  cantly more 
highly expressed in ABC DLBCLs than in GCB DLBCLs 
(4). This fact together with the translocation of SPIB in the 
ABC DLBCL cell line OCI-Ly3 suggests that SPIB may play 
an important role in the pathophysiology of this lymphoma 
subtype. More generally, we believe that the present study 
indicates that a comprehensive identifi  cation of switch trans-
locations in ABC DLBCL is likely to uncover additional 
  oncogenic pathways in this lymphoma type.
MATERIALS AND METHODS
Patient samples. Tumor biopsy specimens, which have previously been 
analyzed by gene expression profi  ling (4, 5), were obtained before treatment 
from 92 patients with DLBCL and 17 patients with MALT lymphoma. All 
samples were studied according to a protocol approved by the NCI Institu-
tional Review Board.
Culture of lymphoma cell lines. Lymphoma cell lines were cultured in 
RPMI, 10% FBS, except for OCI-Ly1, OCI-Ly2, OCI-Ly3, OCI-Ly4, 
OCI-Ly7, OCI-Ly8, and OCI-Ly10, which were cultured in Iscove’s mod-
ifi  ed Dulbecco medium with 20% human plasma.
Southern blot analysis of switch regions. Genomic DNA from cell lines 
and patient samples was extracted with the DNeasy Tissue kit (QIAGEN) 
according to the manufacturer’s instructions. 10 μg of genomic DNA 
was digested with appropriate restriction enzymes, fractionated on a 0.8% 
agarose gel, denatured with a buff  er consisting of 0.5 N NaOH, 0.6 M 
NaCl, neutralized with 1 M Tris-HCL/0.6 M NaCL, and transferred with 
20× SSC to nylon membranes (PerkinElmer). Two radiolabeled probes 
were created by PCR for each Ig switch region, binding either 5′ or 3′ of 
the switch region (Fig. 1) as described previously (28, 33). Filters were 
  hybridized overnight with the radiolabeled probes at 42°C in 1 M NaCl, 
50 mM Tris-HCL, pH 7.4, 40% formamide, 10% dextran sulfate, 1% SDS, 
and 100 μg/ml salmon sperm DNA. The fi  lters were subsequently washed 
in 2× SSC/0.1% SDS at room temperature and then in 0.1× SSC/0.1% 
SDS at 52–60°C, followed by exposure to XAR fi  lms (Kodak) at –70°C 
with an intensifying screen.
The Chi-squared test was used for statistical analysis of the diff  erence in 
CSR events between lymphoma types.
Amplifi  cation and sequencing of aberrant S𝗍 regions MYC, BCL6, 
and SPIB. The Sμ region was amplifi  ed by PCR using primers binding 
5′ and 3′ outside of Sμ (M-F1, G  G  A  G  G  G  G  A  T  G  C  T  C  C  G  G  G  A  A  G  G  T  G  G  ; 
M-R1, C  G  A  G  G  C  A  G  C  C  A  A  C  G  G  C  C  A  C  G  C  ). The PCR was performed 
with TaKaRa La Taq polymerase (Takara Bio, Inc.) using the following 
conditions: 94°C for 1 min, followed by 33 cycles of denaturation, 30 s at 94°C; 
annealing, 30 s at 68°C; extension, 6 min at 72°C; and a fi  nal extension for 642  CSR IN DLBCL LYMPHOMA | Lenz et al.
10 min at 72°C. The PCR products were visualized by electrophoresis on an 
0.8% agarose gel and ethidium bromide staining. PCR products were cloned 
into the Topo XL cloning vector (Invitrogen) and sequenced (BigDye 
  sequencing system; Applied Biosystems).
The PCR reactions for detection of translocations involving the Sμ and 
Sγ region and MYC or BCL6 were performed as described previously (47). 
The PCR reactions to confi  rm a translocation involving the Sγ region and 
SPIB were performed applying one of the SPIB primers (G  G  G  G  C  C  C  T  C  A-
C  T  T  A  C  T  G  T  G   or A  A  C  C  A  G  A  A  G  G  G  G  C  A  A  G  A  G  A  C  ) and one of the Sγ 
primers (G  A  C  C  A  G  T  G  G  A  C  A  C  T  G  T  T  C  T  C  A  G  A  T  G  G   or C  C  T  C  C  A  A  G  G-
C  C  C  T  T  T  T  C  T  T  C  T  G  T  G  ; reference 48) using the following conditions: 
95°C for 10 min, followed by 40 cycles of denaturation, 30 s at 95°C; 
annealing, 30 s at 65°C; extension, 3 min at 72°C, and fi  nal extension for 
10 min at 72°C. The PCR products were visualized by electrophoresis on an 
0.8% agarose gel with ethidium bromide staining, and the PCR product was 
subsequently sequenced.
FISH. FISH for detection of IgH translocations with CH BAC and VH cos-
mid probes was performed as described previously (49). For the analysis of 
SPIB translocation, BAC clones CTB-191K22, CTD-2545M3, and CTD-
2560K21 as well as a whole chromosome painting probe for chromosome 19 
were used. Isolation and labeling of BAC DNA and FISH were performed 
as described previously (50). MYC and BCL6 translocations were detected 
using break-apart probes (Vysis probes; Abbott).
Southern blot analysis of SPIB. 10 μg of genomic DNA was digested 
with SphI, and Southern blotting was performed as described above. A 
radiolabeled 332-bp probe binding  200 bp 3′ of the SPIB start codon was 
created by PCR, and hybridization, washing, and exposure was performed 
as described above.
Gene expression profi  ling. RNA was extracted from the biopsy speci-
mens as described previously (3) and was profi  led for gene expression with 
the use of “Lymphochip” DNA microarrays (51) or Aff  ymetrix U133A and 
U133B oligonucleotide microarrays. The primary gene expression profi  ling 
data are available from the Gene Expression Omnibus of the National Cen-
ter for Biotechnology Information (www.ncbi.nlm.nih.gov/geo) through 
GEO accession number GSE4732.
Online supplemental material. Table S1 and S2 contain the complete 
results of the analysis of class switch recombination by Southern blot in 
  DLBCL cell lines and DLBCL and MALT patient samples. Fig. S1 shows 
lineage models of Sμ alterations in three ABC DLBCL patient samples 
(cases 756, 692, and 645) and two GCB DLBCL patient samples (cases 742 
and 459). Fig. S2 displays sequence analysis of the 5′ end of Sμ deletion in 
ABC DLBCL case 756. The online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20062041/DC1.
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